| Literature DB >> 35645983 |
Eric Goulin Lippi Fernandes1, Sami Ridwan2, Isabell Greeve3, Wolf-Rüdiger Schäbitz3, Alexander Grote1, Matthias Simon1.
Abstract
Background and Purpose: Surgical decompression of the posterior fossa is often performed in cases with a space-occupying cerebellar infarction to prevent coma and death. In this study, we analyzed our institutional experience with this condition. We specifically attempted to address timing issues and investigated the role of cerebellar necrosectomy using imaging data and conducting volumetric analyses.Entities:
Keywords: cerebellar infarction; clinical analysis; decompression; outcome; posterior cranial fossa decompression; space-occupying cerebellar infarction; surgical management; volumetric analysis
Year: 2022 PMID: 35645983 PMCID: PMC9133323 DOI: 10.3389/fneur.2022.840212
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.086
Figure 1Volumetric analysis. (A) CT image of the cerebellum in the coronal plane depicting the segmentation of the posterior cranial fossa (red line) and of the infarcted area (yellow line). The segmentation is performed in the coronal, sagittal, and axial planes and adjusted accordingly for each slice if necessary. (B) Three-dimensional depiction of the cerebellar infarction for illustration purposes. (C) CT image of the cerebellum in the axial plane, with segmentation of residual infarction after necrosectomy (inside yellow line). (D) Three-dimensional depiction of the residual cerebellar infarction for illustration purposes.
Baseline clinical and treatment characteristics (n = 49).
|
|
|
|
|---|---|---|
| Age | Median 70.4 (25–75% IQR: 55.5–70.4) yrs | |
| Comorbidities | Arrhythmia | 21 (42.9%) |
| Smoking | 8 (16.3%) | |
| Diabetes | 15 (30.6%) | |
| Coronaryheartdisease | 10 (20.4%) | |
| Hypertension | 34 (69.4%) | |
| Anticoagulation and/or platelet inhibition | No | 38 (77.6%) |
| Platelet inhibitors | 4 (8.2%) | |
| Phenprocoumon | 3 (6.1%) | |
| NOACs | 4 (8.2%) | |
| Clinical presentation | Initial NIHSS score | Median 8 (25–75% IQR: 3–8) |
| GCS score at presentation | Median 15 (25–75% IQR: 13–15) | |
| GCS score beforesurgery | Median 11 (25–75% IQR: 8–14) | |
| Etiology* | Large-arteryatherosclerosis | 10 (20.4%) |
| Cardioembolism | 19 (38.8%) | |
| Other determinedetiology | 7 (14.3%) | |
| Undeterminedetiology | 13 (26.5%) | |
| Treatment | IV thrombolysis | 8 (16.3%) |
| Thrombectomy | 7 (14.3%) | |
| Successfulthrombectomy (TICI 2b/3) | 5 (10.2%) | |
| Time tosurgery | Median 53 (25–75% IQR: 30–89) hrs | |
| Craniotomy/craniectomy | 17/32 (34.7/65.3%) | |
| Duralexpansion | 18/49 (36.7%) | |
| EVD | 26 (52.1%) | |
| VP shunt | 2 (4.1%) |
IQR, interquartile range; yrs., years; NOAC, new oral anticoagulants; NIHSS, National Institutes of Health Stroke; GCS, Glasgow Coma Scale; *, TOAST classification. Figures do not add up to 100% because of rounding error; IV, intravenous; hrs., hours; EVD, external ventricular drain; VP, ventriculo-peritoneal.
Figure 2Migration plot of functional status changes from admission to discharge and during follow-up are shown as a. In (A) GCS scores at admission, before surgery, and at discharge are displayed for all patients. In panel (B) mRS scores at discharge, at 3 months and 1 year after surgery are shown in n = 33 patients for whom complete data were available. GCS, Glasgow Coma Scale; mRS, modified Rankin Scale.
Imaging findings.
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
| |
|
|
|
PICA, posterior inferior cerebellar artery; SUCA, superior cerebellar artery; VA, vertebral artery; BA, basilar artery; IQR, interquartile range.
Functional outcomes after surgery over time.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Discharge ( | 0 | 3 (6.1%) | 4 (8.2%) | 11 (22.4%) | 13 (26.5%) | 13 (26.5%) | 5 (10.2%) |
| 3 months ( | 1 (2.4%) | 4 (9.8%) | 7 (17.1%) | 8 (19.5%) | 10 (24.4%) | 3 (7.3%) | 8 (19.5%) |
| 1 yr ( | 2 (6.1%) | 6 (18.2%) | 4 (12.1%) | 6 (18.2%) | 2 (6.1%) | 0 | 13 (39.4%) |
| Last f-UP ( | 2 (4.1%) | 9 (18.4%) | 6 (12.2%) | 10 (20.4%) | 8 (16.3%) | 1 (2.0%) | 13 (26.5%) |
mRS, modified Rankin Scale; yr, year; f-up, follow-up.
Figure 3Kaplan Meier estimation of overall survival.
Patient, infarct and treatment characteristics as predictors of in-hospital death, and functional outcomes at discharge and last follow-up.
|
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |||
| Age | ≤ 70 yrs. (median) | 24 (49.0%) | 23 (95.8%) | 1 (4.2%) | 0.349 | 12 (50.0%) | 12 (50.0%) | 0.059 | 18 (75.0%) | 6 (25.0%) | 0.006 |
| >70 yrs. | 25 (51.0%) | 21 (84.0%) | 4 (16.0%) | 6 (24.0%) | 19 (76.0%) | 9 (36.0%) | 16 (64.0%) | ||||
| Sex | Female | 15 (30.6%) | 13 (86.7%) | 2 (13.3%) | 0.635 | 6 (40.0%) | 9 (60.0%) | 0.753 | 7 (46.7%) | 8 (53.3%) | 0.430 |
| Male | 34 (69.4%) | 31 (91.2%) | 3 (8.8%) | 12 (35.3%) | 22 (64.7%) | 20 (58.8%) | 14 (41.2%) | ||||
| Arrhythmia | Yes | 21 (42.9%) | 18 (85.7%) | 3 (14.3%) | 0.639 | 8 (38.1%) | 13 (61.9%) | 0.864 | 12 (57.1%) | 9 (42.9%) | 0.136 |
| No | 28 (57.1%) | 26 (92.9%) | 2 (7.1%) | 10 (35.7%) | 18 (64.3%) | 10 (35.7%) | 18 (64.3%) | ||||
| Smoking | Yes | 8 (16.3%) | 8 (100%) | 0 (0%) | 0.575 | 4 (50%) | 4 (50%) | 0.443 | 6 (75.0%) | 2 (25.0%) | 0.269 |
| No | 41 (83.7%) | 36 (87.8%) | 5 (12.2%) | 14 (34.1%) | 27 (65.9%) | 21 (51.2%) | 20 (48.8%) | ||||
| Diabetes | Yes | 15 (30.6%) | 13 (86.7%) | 2 (13.3%) | 0.635 | 4 (26.7%) | 11 (73.3%) | 0.521 | 6 (40.0%) | 9 (60.0%) | 0.158 |
| No | 34 (69.4%) | 31 (91.2%) | 3 (8.8%) | 14 (42.2%) | 20 (58.8%) | 21 (61.8%) | 13 (38.2%) | ||||
| Coronaryheartdisease | Yes | 11 (22.4%) | 11 (100%) | 0 (0%) | 0.574 | 4 (36.4%) | 7 (63.6%) | 1.000 | 8 (72.7%) | 3 (27.3%) | 0.303 |
| No | 38 (77.6%) | 33 (86.8%) | 5 (13.2%) | 14 (36.8%) | 24 (63.2%) | 19 (50.0%) | 19 (50.0%) | ||||
| Hypertension | Yes | 34 (69.4%) | 30 (88.2%) | 4 (11.8%) | 1.000 | 13 (38.2%) | 21 (61.8%) | 1.000 | 17 (50.0%) | 17 (50.0%) | 0.358 |
| No | 15 (30.6%) | 14 (93.3%) | 1 (6.7%) | 5 (33.3%) | 10 (66.7%) | 10 (66.7%) | 5 (33.3%) | ||||
| Anticoagulation or platelet inhibition | no | 38 (77.6%) | 37 (97.4%) | 1 (2.6%) | <0.001 | 17 (44.7%) | 21 (55.3%) | 0.148 | 23 (60.5%) | 15 (39.5%) | 0.239 |
| Platelet inhibitors | 4 (8.2%) | 3 (75.0%) | 1 (25.0%) | 0 (0%) | 4 (100%) | 2 (50.0%) | 2 (50.0%) | ||||
| Phenprocoumon | 3 (6.1%) | 0 (0%) | 3 (100%) | 0 (0%) | 3 (%) | 0 (0%) | 3 (%) | ||||
| NOACs | 4 (8.2%) | 4 (0%) | 0 (0%) | 1 (25.0%) | 3 (75.0%) | 2 (50.0%) | 2 (50.0%) | ||||
| NIHSS score at presentation | ≤ 4 | 19 (38.8%) | 19 (100%) | 0 (0%) | 0.053 | 13 (68.4%) | 6 (31.6%) | 0.003 | 15 (78.9%) | 4 (21.1%) | 0.032 |
| 5 | 21 (42.9%) | 18 (85.7%) | 3 (14.3%) | 3 (14.3%) | 18 (85.7%) | 8 (38.1%) | 13 (61.9%) | ||||
| ≥16 | 9 (18.4) | 7 (77.8%) | 2 (22.2%) | 2 (22.2%) | 7 (77.8%) | 4 (44.4%) | 5 (55.6%) | ||||
| GCS score at presentation | 14 | 35 (71.4%) | 32 (91.4%) | 3 (8.6%) | 0.616 | 15 (42.9%) | 20 (57.1%) | 0.202 | 20 (57.1%) | 15 (42.9%) | 0.650 |
| ≤ 13 | 14 (28.6%) | 12 (85.7%) | 2 (14.3%) | 3 (21.4%) | 11 (78.5%) | 7 (50.0%) | 7 (50.0%) | ||||
| GCS score at presentation | 14 | 35 (71.4%) | 32 (91.4%) | 3 (8.6%) | 0.810 | 15 (42.9%) | 20 (57.1%) | 0.270 | 20 (57.1%) | 15 (42.9%) | 0.902 |
| 9 | 8 (16.3%) | 7 (87.5%) | 1 (12.5%) | 7 (87.5%) | 1 (12.5%) | 4 (50.0%) | 4 (50.0%) | ||||
| 3 | 6 (12.2%) | 5 (83.3%) | 1 (16.7%) | 4 (66.7%) | 2 (33.3%) | 3 (50.0%) | 3 (50.0%) | ||||
| GCSscore before surgery | 14 | 14 (28.6%) | 12 (85.7%) | 2 (14.3%) | 0.616 | 6 (42.9%) | 8 (57.1%) | 0.574 | 9 (64.3%) | 5 (35.7%) | 0.530 |
| ≤ 13 | 35 (71.4%) | 32 (71.4%) | 3 (8.6%) | 12 (34.3%) | 23 (65.7%) | 18 (51.4%) | 17 (48.5%) | ||||
| GCS score before surgery | 14 | 14 (28.6%) | 12 (85.7%) | 2 (14.3%) | 0.683 | 6 (42.9%) | 8 (57.1%) | 0.721 | 9 (64.3%) | 5 (35.7%) | 0.705 |
| 9 | 18 (36.7%) | 18 (100%) | 0 (0%) | 7 (38.9%) | 11 (61.1%) | 9 (50.0%) | 9 (50.0%) | ||||
| 3 | 17 (34.7%) | 14 (82.4%) | 3 (17.6%) | 5 (29.4%) | 12 (70.6%) | 9 (52.9%) | 8 (47.1%) | ||||
| GCS score deterioration before surgery | Yes | 33 (67.3%) | 30 (90.9%) | 3 (9.1%) | 1.000 | 13 (39.4%) | 20 (60.6%) | 0.579 | 16 (48.5%) | 17 (51.5%) | 0.181 |
| No | 16 (32.7%) | 14 (87.5%) | 2 (12.5%) | 5 (31.3%) | 11 (68.8%) | 11 (68.8%) | 5 (31.3%) | ||||
| Hydrocephalus | Yes | 30 (61.2%) | 27 (90.0%) | 3 (10.0%) | 1.000 | 16 (53.3%) | 14 (46.7%) | 0.003 | 18 (60.0%) | 12 (40.0%) | 0.386 |
| No | 19 (38.8%) | 17 (89.5%) | 2 (10.5%) | 2 (10.5%) | 17 (89.5%) | 9 (47.4%) | 10 (52.6%) | ||||
| Brainstem involvement | Yes | 12 (24.5%) | 10 (83.3%) | 2 (16.7%) | 0.584 | 1 (8.3%) | 11 (91.7%) | 0.036 | 4 (33.3%) | 8 (66.7%) | 0.104 |
| No | 37 (75.5%) | 34 (91.9%) | 3 (8.1%) | 17 (45.9%) | 20 (54.1%) | 23 (62.2%) | 14 (37.8%) | ||||
| Bilateral infarcts | Yes | 14 (28.6%) | 14 (100%) | 0 (0%) | 0.303 | 5 (35.7%) | 9 (64.3%) | 0.925 | 9 (64.3%) | 5 (35.7%) | 0.414 |
| No | 35 (71.4%) | 30 (85.7%) | 5 (14.3%) | 13 (37.1%) | 22 (62.9%) | 18 (51.4%) | 17 (48.6%) | ||||
| Supratentorial infarcts | Yes | 9 (18.4%) | 8 (88.9%) | 1 (11.1%) | 1.000 | 3 (33.3%) | 6 (66.7%) | 1.000 | 6 (66.7%) | 3 (33.3%) | 0.48 |
| No | 40 (81.6%) | 36 (90.0%) | 4 (10.0%) | 15 (37.5%) | 25 (62.5%) | 21 (52.5%) | 19 (47.5%) | ||||
| Etiology | Large-arteryatherosclerosis | 10 (20.4%) | 9 (90.0%) | 1 (10.0%) | 0.974 | 2 (20.0%) | 8 (80.0%) | 0.219 | 3 (30.0%) | 7 (70.0%) | 0.311 |
| Cardioembolism | 19 (38.8%) | 17 (89.5%) | 2 (10.5%) | 10 (52.6%) | 9 (47.4%) | 11 (57.9%) | 8 (42.1%) | ||||
| Other determined etiology | 7 (14.3%) | 6 (85.7%) | 1 (14.3%) | 3 (42.9%) | 4 (57.1%) | 5 (71.4%) | 2 (28.6%) | ||||
| Undetermined etiology | 13 (26.5%) | 12 (92.3.8%) | 1 (7.7%) | 3 (23.1%) | 10 (76.9%) | 8 (61.5%) | 5 (38.5%) | ||||
| Previous IV thrombolysis | Yes | 8 (16.3%) | 7 (87.5%) | 1 (12.5%) | 1.000 | 1 (12.5%) | 7 (87.5%) | 0.229 | 4 (50.0%) | 4 (50.0%) | 0.751 |
| No | 41 (83.7%) | 37 (90.2%) | 4 (9.8%) | 17 (41.5%) | 24 (58.5%) | 23 (56.1%) | 18 (43.9%) | ||||
| Previous thrombectomy | Yes | 7 (14.3%) | 6 (85.7%) | 1 (14.3%) | 0.554 | 0 (0%) | 7 (100%) | 0.038 | 1 (14.3%) | 6 (85.7%) | 0.036 |
| No | 42 (85.7%) | 38 (90.5%) | 4 (9.5%) | 18 (42.9%) | 24 (57.1%) | 26 (61.9%) | 16 (38.1%) | ||||
| Successful thrombectomy | Yes | 5 (10.2%) | 4 (80.0%) | 1 (20.0%) | 0.430 | 0 (0%) | 5 (100%) | 0.143 | 1 (20.0%) | 4 (80.0%) | 0.160 |
| No | 44 (89.8%) | 40 (90.9%) | 4 (9.1%) | 18 (40.9%) | 26 (59.1%) | 26 (59.1%) | 18 (40.9%) | ||||
| Preoperative Kirollos grade | I | 1 (2.0%) | 1 (100%) | 0 (0%) | 0.101 | 0 (0%) | 1 (100%) | 0.143 | 1 (100%) | 0 (0%) | 0.965 |
| II | 16 (32.7%) | 16 (100%) | 0 (0%) | 4 (25.0%) | 12 (75.0%) | 8 (50.0%) | 8 (50.0%) | ||||
| III | 32 (65.3%) | 27 (84.4%) | 5 (15.6%) | 14 (43.8%) | 18 (56.3%) | 18 (56.3%) | 14 (43.8%) | ||||
| Postoperative Kirollos grade | I | 6 (12.2%) | 6 (100%) | 0 (0%) | 0.273 | 1 (16.7%) | 5 (83.3%) | 0.229 | 3 (50.0%) | 3 (50.0%) | 0.585 |
| II | 23 (46.9%) | 21 (91.3%) | 2 (8.7%) | 7 (30.4%) | 16 (69.4%) | 12 (52.2%) | 11 (47.8%) | ||||
| III | 20 (40.8%) | 17 (85.0%) | 3 (15.0%) | 10 (50.0%) | 10 (50.0%) | 12 (60.0%) | 8 (40.0%) | ||||
| Cerebellar infarct volume | ≥64.7 ml (mean) | 20 (40.8%) | 16 (80.0%) | 4 (20.0%) | 0.144 | 5 (25.0%) | 15 (75.0%) | 0.230 | 10 (50.0%) | 10 (50.0%) | 0.551 |
| <64.7 ml | 29(59.2%) | 28 (96.6%) | 1 (3.4%) | 13 (44.8%) | 16 (55.2%) | 17 (58.6%) | 12 (41.4%) | ||||
| Post-surgical infarct volume | ≥34.8 ml (mean) | 20 (40.8%) | 16 (80.0%) | 4 (20.0%) | 0.144 | 6 (30.0%) | 14 (70.0%) | 0.417 | 11 (55.0%) | 9 (45.0%) | 0.990 |
| <34.8 ml | 29 (59.2%) | 28 (96.6%) | 1 (3.4%) | 12 (41.4%) | 17 (58.6%) | 16 (55.2%) | 13 (44.8%) | ||||
| Cerebellar infarct volume/ posterior fossa volume | ≥33.9% (mean) | 23 (46.9%) | 20 (87.0%) | 3 (13.0%) | 0.655 | 6 (23.1%) | 17 (76.9%) | 0.146 | 12 (52.2%) | 11 (47.8%) | 0.698 |
| <33.9% | 26 (53.1%) | 24 (92.3%) | 2 (7.7%) | 12 (46.2%) | 14 (53.8%) | 15 (57.7%) | 11 (42.3%) | ||||
| Postsurgical infarct volume/ posterior fossa volume | ≥18.1% (mean) | 20(40.8%) | 16 (80.0%) | 4 (20.0%) | 0.144 | 7 (35.0%) | 13 (65.0%) | 0.834 | 11 (55.0%) | 9 (45.0%) | 0.990 |
| <18.1% | 29(59.2%) | 28 (96.6%) | 1 (3.4%) | 11 (37.9%) | 18 (62.1%) | 16 (55.2%) | 13 (44.8%) | ||||
| Time to surgery | ≤ 48 hrs. | 31 (63.3%) | 28 (90.3%) | 3 (9.7%) | 1.000 | 10 (32.3%) | 21 (67.7%) | 0.394 | 17 (54.8%) | 14 (45.2%) | 0.961 |
| >48 hrs. | 18 (36.7%) | 16 (88.9%) | 2 (11.1%) | 8 (44.4%) | 10 (55.5%) | 10 (55.6%) | 8 (44.4%) | ||||
| Craniectomy | Yes | 32 (65.3%) | 29 (90.6%) | 3 (9.4%) | 1.000 | 10 (31.3%) | 22 (68.8%) | 0.275 | 17 (53.1%) | 15 (46.9%) | 0.703 |
| No | 17 (34.7%) | 15 (88.2%) | 2 (11.8%) | 8 (47.1%) | 9 (52.9%) | 10 (58.8%) | 7 (41.2%) | ||||
| Dural expansion | Yes | 18 (36.7%) | 17 (94.4%) | 1 (5.6%) | 0.639 | 6 (33.3%) | 12 (66.7%) | 0.707 | 11 (61.1%) | 7 (38.9%) | 0.519 |
| No | 31 (63.3%) | 27 (87.1%) | 4 (12.9%) | 12 (38.7%) | 19 (61.3%) | 16 (51.6%) | 15 (48.4%) | ||||
| Preoperative EVD | Yes | 26 (53.1%) | 23 (88.5%) | 3 (11.5%) | 1.000 | 13 (50.0%) | 13 (50.0%) | 0.074 | 16 (61.5%) | 10 (38.5%) | 0.336 |
| No | 23 (46.9%) | 21 (91.3%) | 2 (8.7%) | 5 (21.7%) | 18 (78.3%) | 11 (47.8%) | 12 (52.2%) | ||||
mRS, modified Rankin Scale; f-up, follow-up; yrs., years; NIHSS, National Institutes of Health Stroke Scale; GCS, Glasgow Coma Scale;
TOAST classification. Figures do not add up to 100% because of rounding error;
TICI grade 2b/3, VA/BA, vertebral/basilar artery; IV, intravenous; hrs., hours.